An interventional study of corticotropin releasing hormone (CRH) and Placebo in Hypopituitarism, sponsored by Max-Planck-Institute of Psychiatry. Completed at 1 site in Germany. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-05-12.
Sponsored by Max-Planck-Institute of Psychiatry · Not applicable, Interventional, and Basic science
In contrast to healthy subjects, patients with hypopituitarism do not exhibit endocrine responses when hormones are injected. This is at least true for those with a complete insufficiency of the anterior pituitary. For example, administration of corticotropin releasing hormone (CRH) is not followed by an increase of ACTH and cortisol. Therefore, "pure" hormone effects can be investigated.
It is well established that hormones of the hypothalamic-pituitary-adrenal axis are involved in sleep regulation. In rodents, CRH decreased slow wave sleep (SWS). In humans, CRH was reported to increase wakefulness and to decrease SWS and REM sleep. Primary objective was therefore to study the effect of CRH on patients with hypopituitarism.
To date, there is no information on sleep of patients with hypopituitarism. Secondary objective is therefore to compare sleep of patients with hypopituitarism with sleep of age-matched healthy controls.
47 studies on the registry are indexed under Hypopituitarism; 8 are open to participants now.
This study's planned enrollment of 30 is below the median of 38 across 29 interventional studies indexed under Hypopituitarism.
Browse Hypopituitarism studies →Max-Planck-Institute of Psychiatry is the lead sponsor of 19 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with hypopituitarism
Inclusion Criteria:
Exclusion Criteria:
Healthy controls
Inclusion Criteria:
Exclusion Criteria:
Patients with hypopituitarism Cross over design: see interventions 1-2
Other: corticotropin releasing hormone (CRH) · Other: Placebo
Parallel design: Healthy controls to be compared with placebo condition in patients with hypopituitarism
Other: Placebo
50 µg injected at 2200, 2300, 0000, and 0100
injected at 2200, 2300, 0000, and 0100
injected at 2200, 2300, 0000, and 0100
Sleep-EEG variables, conventionally and quantitatively analyzed
Time frame: within the first month
The record gives a start of Feb 2008, a primary completion of Oct 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Max-Planck-Institute of Psychiatry